General session III and award ceremony II

 General hepatology
 Webcasted session

Main Plenary
English
Science/Research
14 April 2018 10:00 - 12:00


Presentations

GS-013 Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis c: the Navigator-II study
Roberta D'Ambrosio , Italy
14 April 2018 10:00 - 10:15

Abstract
GS-014 NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks
Stephen Harrison , United States
14 April 2018 10:15 - 10:30

Abstract
GS-015 Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis
Jasmohan S Bajaj , United States
14 April 2018 10:30 - 10:45

Abstract
Award ceremony 2
14 April 2018 10:45 - 11:15

GS-016 A phase 1/2, randomized, placebo controlled an open label extension studies of Givosiran and investigational RNA interference therapeutic, in patients with acute intermittent porphyria
Eliane Sardh , Sweden
14 April 2018 11:15 - 11:30

Abstract
GS-017 Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis
Sharon Hutchinson , United Kingdom
14 April 2018 11:30 - 11:45

Abstract
GS-018 Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with Sofosbuvir-based regimens
Alessandra Mangia , Italy
14 April 2018 11:45 - 12:00

Abstract